Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors ...
Hosted on MSN2mon
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for ...
Hosted on MSN2mon
Gilead and LEO Pharma link on programmes for inflammatory conditionsGilead will acquire LEO Pharma's preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will spearhead further development of the oral programmes, while LEO Pharma ...
Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors ...
Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...
Research and development expenses rose to $71.8 million in the fourth quarter, up from $53.0 million a year earlier, as the company increased investment in its STAT6 and TYK2 degrader programs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback